Ozempic can reduce metabolic risks in schizophrenia patients, multicenter study finds

Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uv…

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ...

Study establishes practical definition for rapidly progressive dementia

A new multicenter study led by Mayo Clinic researchers has established a practical, evidence-based definition of rapidly progressive dementia (RPD), a rare but devastating form of cognitive decline ...
TipRanks on MSN

Organogenesis nears key data milestone with phase 3 knee osteoarthritis study

Organogenesis Holdings ($ORGO) announced an update on their ongoing clinical study. Study Overview Organogenesis Holdings (ORGO) is sponsoring a ...
ascopubs.org

ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine ...

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation Eligible patients ...
Pharmabiz

Combination of Castle Biosciences’ DecisionDx-UM and PRAME show predicting outcomes in patients with uveal melanoma: Study

Combination of Castle Biosciences’ DecisionDx-UM and PRAME show predicting outcomes in patients with uveal melanoma: Study: Friendswood, Texas Friday, December 19, 2025, 15:00 H ...